Related Experiment Video
Updated: Sep 28, 2025
02:28
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
522
Psoriatic arthritis: prospects for the future.
Simon Hackett1, Alexis Ogdie2, Laura C Coates3
1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Therapeutic Advances in Musculoskeletal Disease
|April 4, 2022
Summary
Psoriatic arthritis (PsA) presents diverse symptoms and challenges in diagnosis and treatment. Early identification and effective management of PsA are crucial unmet needs for improving patient quality of life.
Area of Science:
- Rheumatology and Immunology
- Dermatology
Background:
- Psoriatic arthritis (PsA) is a chronic inflammatory condition linked to psoriasis, causing joint pain, swelling, and other symptoms.
- PsA exhibits significant heterogeneity, leading to variable clinical courses and potential for rapid joint destruction.
- The disease often impairs quality of life due to joint damage, chronic pain, and comorbidities like depression and cardiovascular disease.
Purpose of the Study:
- To review current challenges in diagnosing and managing psoriatic arthritis.
- To identify unmet medical needs in early PsA identification, diagnosis, and treatment response prediction.
- To propose future action points for multidisciplinary teams treating PsA patients.
Main Methods:
- Literature review of current diagnostic and management strategies for PsA.
- Analysis of diagnostic criteria, including the CASPAR criteria.
- Examination of emerging biological therapies and their clinical utility.
Main Results:
- Diagnosis of PsA remains challenging due to its heterogeneous presentation and lack of definitive tests.
- While treatment options have expanded, early identification and predicting treatment response are significant unmet needs.
- Current management strategies face hurdles in achieving effective disease control for all PsA patients.
Conclusions:
- Addressing diagnostic and management challenges in PsA is critical for improving patient outcomes.
- Further research and multidisciplinary collaboration are needed to overcome unmet medical needs in PsA.
- Enhanced strategies for early PsA detection and personalized treatment are essential.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
14.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.5K
01:26Atherosclerosis III: Management
54
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
54
01:21Rheumatic Heart Disease III: Medical Management
46
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
46
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
265
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
265
01:23Rheumatic Heart Disease I: Introduction
63
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
63
01:30Peripheral Artery Disease I: Introduction
57
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
57